KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Current Quarter	$-0.83	Next Quarter	$-0.59
Current Year	$-2.72	Next Year	$-2.41
QoQ Growth	+28.9%	YoY Growth	+11.4%
3Y EPS CAGR	-3.2%	Target Price	$31.00
Consensus	Buy	Upside	+136.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KALV	$13.10	+0.61%	989.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KALV	$13.10	+0.6%	989.31K
3
4
5
6

KALV

KALV

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get KalVista Pharmaceuticals Inc. Data in Excel

Get KalVista Pharmaceuticals Inc. Data in Excel